viewOpen Orphan PLC

Open Orphan signs option agreement to buy business that makes agents used in challenge studies

If the acquisition goes ahead, CHIMagents will operate as a standalone company within the larger business

Open Orphan PLC -

Open Orphan PLC (LON:ORPH) said it has signed an option agreement to acquire a company called CHIMagents for a nominal sum.

The business designs, manufactures, and tests agents for use in challenge studies, which complements the work carried out in the infectious diseases field by Open Orphan subsidiary hVIVO.

CHIMagent's Adrian Wildfire, who has over 20 years of industry experience, will join hVIVO as a director.

Open Orphan chief executive Cathal Friel said the option agreement was an “important strategic step as we rapidly grow our pipeline of challenge studies”.

“The work CHIMagents is undertaking in relation to COVID-19 challenge agents also complements our own work and we look forward to updating all shareholders on that workstream in due course,” he added in a statement.

“We have real momentum across the group and this option further cements our position as one of the leading service providers to the developers of vaccines and anti-virals globally."

Open Orphan has three months in which to exercise the option. If the acquisition goes ahead, CHIMagents will operate as a standalone company within the larger business.

Quick facts: Open Orphan PLC

Price: 13.0799 GBX

Market: AIM
Market Cap: £87.06 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



Open Orphan awarded contract from Codagenix for COVID-19 Vaccine Trial

Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after announcing that US biotech Codagenix Inc has commissioned its hVIVO arm to carry out a first-in-human trial of a nasal vaccine for coronavirus. The phase I study of 48 healthy young adults will take place...

6 days, 22 hours ago

2 min read